Although the schizophrenia drug market is crowded, no pharmacological agents are approved specifically to treat cognitive impairment associated with schizophrenia (CIAS) (e.g., impaired attention / vigilance, memory, executive function) in the United States or Europe. In fact, no drugs have demonstrated consistent efficacy in improving cognitive function among the sizeable schizophrenia population with cognitive deficit, and psychiatrists’ treatment options for these patients are limited. Given the paucity of therapeutic options and the long-term impact of cognitive deficits on patients’ quality of life and functioning, there is high unmet need and commercial opportunity for an efficacious and safe therapy to treat CIAS in this underserved schizophrenia segment.
- What is the relative importance of a therapy’s various attributes in psychiatrists’ prescribing decisions for CIAS (e.g., improvement in overall cognition, improvement in patient functioning, improvement in positive and negative symptoms)
- How do U.S. and European psychiatrists rate the performance of various current therapies on key treatment drivers and goals for CIAS?
- What are the prevailing areas of unmet need and opportunity in the treatment of CIAS?
- What trade-offs across key drug attributes and price are acceptable to psychiatrists for a hypothetical new drug for CIAS?
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European psychiatrists fielded in February 2020.
Key companies: Janssen, Otsuka Pharmaceuticals, Novartis, Allergan, Eisai, Teva, Pfizer.
Key drugs: Aripiprazole, rivastigmine, risperidone, memantine, donepezil, modafinil, sertraline.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
- Schizophrenia - Unmet Need - Detailed, Expanded Analysis (Cognitive Impairment)
Author(s): Shefali Gulati, MBA Pharm
Shefali Gulati, Associate analyst, is part of the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group.
She is responsible for performing extensive secondary market research and analysis for major pharmaceutical markets. She comes with one year of experience working on multiple client projects revolving around opportunity assessment, competitive landscape, pipeline analysis, and key product profiling. She holds a MBA degree in Pharmaceutical Management from the National Institute of Pharmaceutical Education and Research (NIPER) in India and Bachelor’s in Pharmacy from DIPSAR.